487 Results

People

  1. De Angelis
    De Angelis
  2. Abrey
    Abrey
  3. Kelsen
    Kelsen
  4. Lichtman
    Lichtman
  5. Bajorin
    Bajorin
  6. Perales
    Perales
  7. Yahalom
    Yahalom
  8. Saltz
    Saltz
  9. Seidman
    Seidman
  10. Correa
    Correa

Groups

  1. Department of Medicine (257)
  2. Solid Tumor Oncology Division (171)
  3. Hematologic Malignancies, Division of (102)
  4. Center for Hematologic Malignancies (89)
  5. Survivorship Research (72)
  6. Tow Center for Developmental Oncology (TCDO) (51)
  7. Gastrointestinal Oncology Service (50)
  8. Surgery (45)
  9. Genitourinary Oncology Service (42)
  10. Bone Marrow Transplant (38)
  1. "neurotoxicity"
Formats
  1. Journal Article (426)
  2. Review (34)
  3. Editorial (6)
  4. Conference Paper (5)
  5. Book Section (4)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Meeting Abstract (2)
  9. Research Letter (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (257)
  2. Solid Tumor Oncology Division (171)
  3. Hematologic Malignancies, Division of (102)
  4. Center for Hematologic Malignancies (89)
  5. Survivorship Research (72)
  6. Tow Center for Developmental Oncology (TCDO) (51)

More Groups

People
  1. Lisa De Angelis (44)
  2. Lauren Abrey (29)
  3. David Kelsen (19)
  4. Stuart Lichtman (18)
  5. Dean Bajorin (17)
  6. Joachim Yahalom (17)

More People

Years
  1. 2025 (25)
  2. 2024 (26)
  3. 2023 (18)
  4. 2022 (10)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (46)
  2. Cancer (19)
  3. Seminars in Oncology (15)
  4. Gynecologic Oncology (13)
  5. Journal of Neuro-Oncology (13)
  6. Blood (11)

More Publications

Publishers
  1. Elsevier Inc. (80)
  2. American Society of Clinical Oncology (47)
  3. Springer (41)
  4. Nature Publishing Group (28)
  5. Wiley Blackwell (27)
  6. Lippincott Williams & Wilkins (26)

More Publishers

Results (487)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study
    Journal Article

    Tan, C. R.; Asoori, S.; Huang, C. Y.; Brunaldi, L.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Bansal, R.; Silva Corraes, A. D. M.; Chhabra, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
    Journal Article

    Shahid, S.; Prockop, S. E.; Flynn, G. C.; Mauguen, A.; White, C. O.; Bieler, J.; McAvoy, D.; Hosszu, K.; Cancio, M. I.; Jakubowski, A. A.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Outcomes of older adults and frail patients receiving idecabtagene vicleucel: A CIBMTR study
    Research Letter

    Akhtar, O. S.; Oloyede, T.; Brazauskas, R.; Afrough, A.; Hashmi, H.; Sidana, S.; Ahmed, N.; Bye, M.; Hansen, D.; Ferreri, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Consolidation regimen and cerebral atrophy in patients with primary central nervous system lymphoma
    Journal Article

    Tringale, K. R.; Grommes, C.; Ucpinar, B. A.; Reiner, A. S.; Yahalom, J.; Cederquist, G. Y.; Schaff, L. R.; Hatzoglou, V.; Young, R. J.; Payinkay, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save
  • Development of ALL-Hematotox: Predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
    Journal Article

    Nair, M. S.; Silbert, S. K.; Rejeski, K.; Wilson, K. A.; Lamble, A. J.; Valtis, Y.; Yates, B.; Morales Arana, A.; Shouval, R.; Curran, K.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Neurotoxicity and rare adverse events in BCMA-Directed CAR t cell therapy: A comprehensive analysis of real-world FAERS data
    Journal Article

    Ellithi, M.; Elsallab, M.; Lunning, M. A.; Holstein, S. A.; Sharma, S.; Trinh, J. Q.; Ma, J.; Maus, M. V.; Frigault, M. J.; D'Angelo, C. R.
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity
    Journal Article

    Vogt, K. C.; Silberman, P. C.; Lin, Q.; Han, J. E.; Laflin, A.; Gellineau, H. A.; Heller, D. A.; Scheinberg, D. A.
    Science Advances (2025)

    Fulltext@MSK | Save
  • Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: Subgroup analyses from the CIBMTR registry
    Journal Article

    Landsburg, D. J.; Frigault, M. J.; Heim, M.; Foley, S. R.; Hill, B.; Schofield, G.; Jacobson, C. A.; Jaglowski, S.; Locke, F. L.; Ram, R.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Safety and tolerability of letetresgene autoleucel (GSK3377794): Pilot studies in patients with advanced non–small cell lung cancer
    Journal Article

    Altan, M.; Lopes, G.; Hiltermann, T. N. J.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
    Review

    Sands, J. M.; Champiat, S.; Hummel, H. D.; Paulson, K. G.; Borghaei, H.; Alvarez, J. B.; Carbone, D. P.; Carlisle, J. W.; Choudhury, N. J.; Clarke, J. M.; more...
    Cancer (2025)

    Fulltext@MSK | Save